In multiple myeloma (MM), the latest preclinical trial has confirmed that when combined with daratumumab, expanded g-NK cells with low CD38 expression and potent ADCC activity presented dramatically superior curative and persistence than conventional NK cells [105]. The gene discussed is CD38; the disease is plasma cell myeloma.